Clinical Trial Update: Pearlium®/Effecti-Cal®, a Novel Formulation of Calcium, Vitamin D and Minerals for Prevention of Postmenopausal Bone Loss [Phase 4]

View source ↗

Summary

Phase 4 trial update on Pearlium®/Effecti-Cal®, a calcium, vitamin D and minerals formulation for prevention of postmenopausal bone loss.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Pearlium®/Effecti-Cal® (calcium, vitamin D and minerals formulation)

Snippet

Sponsor: University of Alberta | Conditions: Osteoporosis, Postmenopausal | Phase 4 | Status: COMPLETED